Compare Regeneron Pharmaceuticals Inc (REGN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wendys Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.9 (market cap $76.14B), while Wendys Co trades at $6.16 (market cap $1.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 64× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Wendys Co for 77 Days on average.
| REGN | WEN | |
|---|---|---|
Market Cap | $76.14B | $1.19B |
Volume | 500,239 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $9.33 |
52-Week Low | $557.73 | $6.10 |
Typical Hold Time | 107 Days | 77 Days |
Enterprise Value | $70.85B | $4.92B |
Dividend Yield | 0.51% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Wendy's stock (WEN) trades at $6.11, down 0.81% on the day, reflecting ongoing pressure from declining sales and a major franchisee bankruptcy. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a low P/E of 9.45 and strong ROE of 108.04%, but net income margins have fallen to 5.72%. Recent news highlights competitive struggles and store closures, though the company continues to beat earnings expectations.
The outlook remains cautious due to operational headwinds and high debt, but the current valuation may appeal to value investors. Risks include franchisee instability and intense competition. Analyst consensus is mixed with a $7.58 price target, suggesting limited upside from current levels amid uncertain recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
